logo

For the Inventor, By the Inventor

Princeton, NJ, United States of America

Don Zhang

LinkedIn
USPTO Granted Patents = 16 

 

 

Average Co-Inventor Count = 4.8

ph-index = 3

Forward Citations = 13(Granted Patents)


Location History:

  • Old Lyme, CT (US) (2006)
  • Branford, CT (US) (2014 - 2015)
  • Plainsboro, NJ (US) (2016 - 2018)
  • Princeton, NJ (US) (2019 - 2022)

Company Filing History:

goldMedal16 out of 16 
 
Beta Pharma, Inc.
 patents
silverMedal1 out of 1 
 
Beta Pharma (shanghai) Co., Ltd.
 patent
where one patent can have more than one assignee

Years Active: 2006-2025

Loading Chart...
Loading Chart...
Loading Chart...
16 patents (USPTO):Explore Patents
1. 12390464 - Treatment of EGFR mutant-related cancers using a combination of EGFR and CDK4/6 inhibitors (2025-08-19),
2. 12258365 - Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof (2025-03-25),
3. 12187707 - Pharmaceutical formulations of-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylaminde and salts thereof (2025-01-07),
4. 11414401 - Substituted 2-anilinopyrimidine derivatives as EGFR modulators (2022-08-16),
5. 11352341 - 2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof (2022-06-07),
6. 11180478 - Pharmaceutical formulations of N-(2-(2-(dimethylamino) ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof (2021-11-23),
7. 11052086 - 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers (2021-07-06),
8. 10844045 - Pharmaceutical salts N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof (2020-11-24),
9. 10590111 - Substituted 2-anilinopyrimidine derivatives as EGFR modulators (2020-03-17),
10. 10239864 - 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof (2019-03-26),
11. 9878994 - 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof (2018-01-30),
12. 9820721 - Aspiration and biopsy needle apparatus and devices and applications thereof (2017-11-21),
13. 9359370 - Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof (2016-06-07),
14. 9163010 - Indolinone protein kinase inhibitors (2015-10-20),
15. 8822482 - Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof (2014-09-02),

Title: The Innovator Extraordinaire: Don Zhang

Introduction:

Don Zhang, a prolific inventor based in Princeton, NJ, has made significant contributions to the field of pharmaceuticals and cancer research with a total of 13 patents under his belt.

Latest Patents:

Don Zhang's recent patents showcase his groundbreaking work in the development of novel pharmaceutical compounds. These include "Substituted 2-anilinopyrimidine derivatives as EGFR modulators" and "2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof". These inventions hold immense promise for the treatment and prevention of diseases mediated by epidermal growth factor receptors and cyclin-dependent kinases.

Career Highlights:

Having worked with esteemed companies such as Beta Pharma, Inc. and Beta Pharma (Shanghai) Co., Ltd., Don Zhang has established himself as a key figure in the pharmaceutical industry. His patents not only demonstrate his technical acumen but also his drive to improve healthcare outcomes.

Collaborations:

Throughout his career, Don Zhang has collaborated with esteemed colleagues like Jirong Peng and Michael Nicholas Greco. These partnerships have been instrumental in advancing his research and bringing innovative pharmaceutical solutions to the market.

Conclusion:

Don Zhang's innovative spirit and dedication to advancing healthcare make him a standout figure in the world of inventors. His pioneering work in developing pharmaceutical compounds underscores his commitment to improving the lives of those affected by various diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…